Triple drug combination targeting KRAS pathway eliminates pancreatic tumors in preclinical study

Researchers have shown that blocking the KRAS signaling pathway at three separate points simultaneously can eliminate pancreatic tumors in preclinical models. The study, which used a combination of three targeted drugs rather than the single or dual inhibitor approaches that have dominated KRAS research for the past decade, produced complete tumor regression in mouse models where single-agent KRAS inhibitors had previously failed to sustain a response.

Pancreatic cancer kills roughly 90 percent of patients within five years of diagnosis. The five-year survival rate for pancreatic ductal adenocarcinoma, which accounts for about 90 percent of all pancreatic cancers, sits at approximately 12 percent according to the American Cancer Society's 2024 statistics. One reason the disease is so lethal is that KRAS mutations, present in over 90 percent of pancreatic tumors, drive the cancer's growth in a way that has historically been nearly impossible to shut down pharmacologically. This study is the most direct preclinical evidence yet that a multi-point blockade can overcome that resistance.

Why KRAS has been so hard to target

KRAS encodes a protein that functions as a molecular switch controlling cell growth and division. In normal cells, KRAS turns on in response to growth signals and turns off again. In cancer cells with KRAS mutations, the protein is stuck in the on position, continuously signaling the cell to grow and divide. For decades, KRAS was considered undruggable because its protein surface lacked a pocket where small molecules could bind and block its activity.

That changed in 2021 when the FDA approved sotorasib, the first KRAS inhibitor to reach the market, specifically targeting the KRAS G12C mutation in lung cancer. Pancreatic cancer, however, is predominantly driven by a different KRAS variant called G12D, which lacks the reactive cysteine residue that made G12C druggable with covalent inhibitors. Several KRAS G12D inhibitors entered clinical trials in 2023 and 2024 but produced only modest response rates, typically 20 to 30 percent, with most patients developing resistance within six months.

What the triple drug combination actually does

The three-drug combination in this study targets the KRAS pathway at distinct steps: the KRAS G12D protein itself, a downstream signaling protein called MEK, and a parallel feedback pathway involving SHP2, a phosphatase enzyme that reactivates KRAS signaling when either of the first two targets is blocked alone. That reactivation through SHP2 is the primary mechanism by which pancreatic tumor cells develop resistance to single-agent KRAS or MEK inhibitors.

The logic of the combination is that blocking any one point in the pathway activates compensatory signaling through the other two. Block all three simultaneously, and the cancer cell cannot reroute its growth signals fast enough to survive. In the mouse models tested, all three drugs were required for complete tumor regression. Removing any single drug from the combination allowed tumor regrowth within four weeks, which confirms that the synergistic effect depends on simultaneous inhibition at all three nodes.

The specific drugs used were MRTX1133, a KRAS G12D inhibitor developed by Mirati Therapeutics that is currently in Phase 1/2 clinical trials; trametinib, a MEK inhibitor approved by the FDA for melanoma and lung cancer; and RMC-4550, an SHP2 inhibitor from Revolution Medicines that has completed Phase 1 safety trials. All three compounds have existing human safety data, which shortens the path to a combination clinical trial compared to testing three entirely novel agents.

Toxicity and tolerability in the preclinical models

One of the consistent concerns with combination cancer therapies is that adding drugs multiplies side effects. The research team measured body weight, organ function markers, and behavioral indicators of toxicity in the mouse models receiving all three drugs at therapeutic doses. They reported that the combination was tolerated without significant weight loss or organ toxicity at the doses required to eliminate tumors, though the authors noted that rodent tolerance data does not reliably predict human tolerance and that a dedicated Phase 1 dose-escalation trial would be needed to establish safe dosing in humans.

Each drug in the combination has a known individual side effect profile from human trials. Trametinib is associated with rash, diarrhea, and cardiac effects at higher doses. MRTX1133 showed gastrointestinal toxicity in early Phase 1 data. RMC-4550's Phase 1 results reported peripheral edema and elevated liver enzymes in a subset of patients. Whether those individual effects are additive or manageable at the doses required for the combination is the primary safety question that a human trial would need to answer first.

The team behind the research and where it was published

The study was led by a research group at the University of Texas MD Anderson Cancer Center, with contributions from collaborators at Memorial Sloan Kettering Cancer Center and the Salk Institute for Biological Studies. The paper was published in the journal Cancer Cell in the March 2026 issue. The research was supported by grants from the National Cancer Institute totaling $4.2 million, a Stand Up To Cancer pancreatic cancer research grant of $1.8 million, and industry research agreements with Revolution Medicines and Mirati Therapeutics.

The industry involvement is worth noting in terms of how quickly this could advance. Both Revolution Medicines and Mirati Therapeutics have financial incentives to move their compounds into combination trials, and both have existing clinical infrastructure from ongoing single-agent studies. The MD Anderson team stated in the paper that they are in discussions with both companies about designing a Phase 1/2 combination trial, with a target IND submission to the FDA in the fourth quarter of 2026.

What this means for patients and how far it is from the clinic

Complete tumor elimination in mouse models does not translate automatically to human clinical response. The history of pancreatic cancer research includes numerous preclinical successes that failed to replicate in human trials, including dozens of compounds that cleared mouse studies between 2000 and 2020 before falling apart at Phase 2. The biological environment of a human pancreatic tumor, with its dense fibrous stroma that limits drug penetration, is considerably more challenging than a subcutaneous xenograft in a mouse.

What makes this study different from many earlier preclinical reports is the use of genetically engineered mouse models that develop spontaneous pancreatic tumors with the same KRAS G12D driver mutation and stromal architecture found in human disease, rather than implanted human tumor cells in immunocompromised mice. That model choice is more predictive of human biology, which is why the oncology field has been paying attention to this result in a way that earlier mouse studies did not command.

The researchers also tested the combination in organoids derived from primary human pancreatic tumor tissue collected from surgical patients at MD Anderson. In 11 of 14 patient-derived organoid samples tested, the triple combination reduced tumor cell viability by more than 90 percent. That human tissue data, while not a clinical trial, provides a bridge between the mouse results and what might be expected in human patients and is the detail most oncologists will focus on when evaluating the study's potential.